AnaBios is pleased to announce that Gatehouse Bio Chief Executive Officer Dr. David W. Salzman is the winner of the 2024 Translational Research Grant Award. Dr. Salzman will obtain up to $15,000 in AnaBios’ high-quality precision-cut lung slices to help Gatehouse Bio advance drug development in idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disease characterized by scarring of lung tissue due to an unknown cause. Gatehouse Bio is exploring non-coding RNA referred to as a microRNA, which causes accelerated IPF progression in approximately 70% of cases.
“Donor lung tissue is a critical resource for drug developers that enables drug testing in an ex vivo system prior to clinical trials,” said Dr. Salzman. “We are grateful to AnaBios for making this grant possible, as well as the brave donors and families impacted by IPF.”
The lung tissue provided by AnaBios will be used to further test the delivery, safety and efficacy of Gatehouse Bio’s compound ahead of planned clinical trials.
The top 10 entries into the translational research competition received a 25% discount from AnaBios towards human tissue samples for future research projects.